Casi PharmaceuticalsCASIF
13F holders, Q4 2025 (December 31)At the end of Q4 2025, 16 institutions reported holding Casi Pharmaceuticals Inc. (CASIF) in their 13F filings, down 6 from Q3 2025. 1 opened new positions and 7 sold out. The largest holders were Venrock Adviser, LLC ($839K), Woodline Partners LP ($113K) and Renaissance Technologies ($37K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Casi Pharmaceuticals Inc.
- CUSIP
- G1933S101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $12K |
| Exits | 7 | $1.8M |
All 13F filers, Q3 2025 → Q4 2025: 14,692 shares bought and 1,369,801 shares sold, net −1,355,109 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Venrock Adviser, LLC | 0.04% | No change | 987,259 | $839K |
| Woodline Partners LP | 0.00% | Reduce -19.5% | 133,406 | $113K |
| Renaissance Technologies | 0.00% | Reduce -1.8% | 43,100 | $37K |
| Two Sigma Investments, LP | 0.00% | Reduce -28.5% | 23,787 | $20K |
| Bank of America Corp. | 0.00% | Reduce -92.2% | 19,935 | $17K |
| Geode Capital Management, LLC | 0.00% | No change | 18,808 | $16K |
| Citadel Advisors | 0.00% | New | 14,045 | $12K |
| Royal Bank of Canada | 0.00% | No change | 9,950 | $8K |
| UBS Group AG | 0.00% | Add +4607.1% | 659 | $560 |
| Wells Fargo & Company | 0.00% | No change | 505 | $429 |
| Morgan Stanley | 0.00% | Add +0.6% | 367 | $312 |
| BNP Paribas Financial Markets | 0.00% | No change | 134 | $114 |
| Simplex Trading, LLC | 0.00% | Reduce -8.3% | 133 | $113 |
| JPMorgan Chase & Co. | 0.00% | No change | 25 | $21 |
| Colonial Trust Co / SC | 0.00% | No change | 11 | $9 |
| MAI Capital Management | 0.00% | No change | 5 | $5 |
"% of holder's portfolio" is CASIF's weight in each manager's 13F, not the share of Casi Pharmaceuticals Inc. the manager owns.